In early trials, a new malaria vaccine developed by Oxford University researchers and Burkina Faso scientists proved to be 77 percent successful against the disease, much outperforming any current therapies.
The Lancet research, which included 450 Burkinabe youngsters, is now moving on to large-scale trials.
About 4,800 children under the age of three will be enrolled in the next survey. This event will take place in Burkina Faso, Mali, Kenya, and Tanzania.
“These are extremely encouraging results, showing extraordinary levels of efficacy from a vaccine that was well tolerated in our clinical trial program. We are excited for the upcoming phase III trial, which will provide large-scale safety and efficacy data for a vaccine that is urgently needed in this region,” said Halidou Tinto, a parasitology professor and regional director of Burkina Faso’s Institute of Health Sciences (IRSS).
In Sub-Saharan Africa, the disease claims the lives of over 400,000 people each year, many of whom are children.
Only one vaccine is currently available, and it is only 50% effective.
This latest vaccine demonstrated a 77 percent efficacy rate in stage two trials. It will now go on to bigger examinations, which will be conducted in four African countries.
Children under the age of three would make up almost 5,000 participants.
The effectiveness of this new therapy has yet to be established. However, in a year in which vaccines have demonstrated their importance, it will be viewed as an extremely promising advancement.